Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 22 citing articles:

Adjuvant Immunotherapy Should Be Used in Patients With Non-Small Cell Carcinoma With a Pathologic Complete Response to Neoadjuvant Immunotherapy
Dipesh Uprety, Anja C. Roden, Solange Peters
Journal of Thoracic Oncology (2025) Vol. 20, Iss. 1, pp. 34-38
Closed Access
Navigating the landscape of neoadjuvant immunotherapy for NSCLC: progress and controversies
Yuzhu Chen, Fei Qi, Chao Sun, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Bibliometric insight into neoadjuvant immunotherapy in non-small cell lung cancer: trends, collaborations, and future avenues
Pengliang Xu, Huanming Yu, Hongqiang Bian, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Perioperative Chemo-Immunotherapy in Non-Oncogene-Addicted Resectable Non-Small Cell Lung Cancer (NSCLC): Italian Expert Panel Meeting
Filippo de Marinis, Andrea Ardizzoni, Ilaria Attili, et al.
Current Oncology (2025) Vol. 32, Iss. 2, pp. 110-110
Open Access
Immune Checkpoint Inhibitors and Targeted Therapies in Early-Stage Non-Small-Cell Lung Cancer: State-of-the-Art and Future Perspectives
Lucrezia Barcellini, Simone Nardin, G. Sacco, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 652-652
Open Access
Osimertinib in the Treatment of Epidermal Growth Factor Receptor-Mutant Early and Locally Advanced Stages of Non-Small-Cell Lung Cancer: Current Evidence and Future Perspectives
Antonello Veccia, Mariachiara Dipasquale, M. Lorenzi, et al.
Cancers (2025) Vol. 17, Iss. 4, pp. 668-668
Open Access
First results of a multicenter, non-randomized, prospective phase II study of the efficacy and safety of induction therapy with pembrolizumab, cisplatin, and 5-fluorouracil in patients with unresectable squamous cell carcinoma of the oropharynx, hypopharynx and larynx
O. Stativko, И. А. Покатаев, С А Кравцов, et al.
Journal of Modern Oncology (2025) Vol. 26, Iss. 4, pp. 447-453
Open Access
Real-world comparison of neoadjuvant pembrolizumab plus chemotherapy versus tislelizumab plus chemotherapy in patients with resectable non-small cell lung cancer: a retrospective cohort study of treatment outcomes
Yan Hu, Siying Ren, Juan Feng, et al.
Translational Lung Cancer Research (2025) Vol. 14, Iss. 2, pp. 467-479
Open Access
Overcoming common emerging barriers to effective neoadjuvant immunotherapies
Sophia Sokol, Marijo Bilušić
Expert Review of Anticancer Therapy (2025), pp. 1-11
Closed Access
Immunotherapy in the Management of Penile Cancer—A Systematic Review
Hossein Taghizadeh, Harun Fajković
Cancers (2025) Vol. 17, Iss. 5, pp. 883-883
Open Access
Oncological and Survival Endpoints in Cancer Cachexia Clinical Trials: Systematic Review 6 of the Cachexia Endpoints Series
Olav Dajani, Iain Philips, Ester Kristine Størkson, et al.
Journal of Cachexia Sarcopenia and Muscle (2025) Vol. 16, Iss. 2
Open Access
Efficacy and safety of induction immunochemotherapy followed by radiotherapy for patients with unresectable locally advanced non-small cell lung cancer: A retrospective study
Liu Li-pin, Cui Gao, Yimin Yang, et al.
Radiation Oncology (2025) Vol. 20, Iss. 1
Open Access
NeoTRACK trial: Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – dissection of IO- efficacy in NSCLC by longitudinal tracKing – protocol of a non-randomised, open-label, single-arm, phase II study
Romina Maria Roesch, Johannes Schnorbach, Laura V. Klotz, et al.
BMJ Open (2025) Vol. 15, Iss. 3, pp. e096617-e096617
Open Access
Comparison of programmed death ligand-1 expression in preoperative transbronchial lung biopsy and resected specimens in non-small cell lung cancer
Naoko Shigeta, Shuji Murakami, Kouji Yamamoto, et al.
Journal of Cancer Research and Clinical Oncology (2025) Vol. 151, Iss. 4
Open Access
Current perspective on resectability in stage III locally advanced NSCLC – the thoracic surgeons’ view
Clemens Aigner, Natalie Baldes, Merjem Begic, et al.
European Journal of Cancer (2025) Vol. 221, pp. 115426-115426
Open Access
Neoadjuvant Camrelizumab Plus Chemotherapy or Apatinib for Resectable Stage IIA-IIIA NSCLC: A Multicenter, Two-Arm, Phase II Exploratory Trial
Shuyu Ji, Zhenxin Sheng, Dongliang Bian, et al.
Research Square (Research Square) (2025)
Closed Access
NSCLC: Perioperative PD-1-Inhibition ein echter Schritt nach vorn

Pneumologie (2025) Vol. 79, Iss. 04, pp. 265-265
Closed Access
Optimal timing of cancer treatments: a call for emerging evidence from clinical trials and real-world studies
Jianrong Zhang, Rebecca L. Venchiarutti, Xiaofei Wang, et al.
British Journal of Cancer (2025)
Open Access
Expression of the TIGIT axis and the CD39/CD73 purinergic pathway in bone metastasis-derived immune cells
Elias Brauneck, Leon-Gordian Leonhardt, Anne Marie Assemissen, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 6
Open Access
Difficult Decisions in the Multidisciplinary Treatment of Resectable Non-small Cell Lung Cancer
Wara Naeem, Arsalan Khan, Oluwamuyiwa W. Adebayo, et al.
Annals of Surgical Oncology (2025)
Closed Access
Combination Immunotherapy With Radiotherapy in Non‐Small Cell Lung Cancer: A Review of Evidence
Justin Burr, Kurtis C. Johnson, Joseph Carmicheal, et al.
Cancer Medicine (2024) Vol. 13, Iss. 21
Open Access | Times Cited: 2
Phase II study of perioperative camrelizumab and XELOX for locally advanced gastric or gastroesophageal junction adenocarcinoma
Jiaxing He, Bo Zhang, Shuai Zhou, et al.
Cancer Science (2024)
Open Access | Times Cited: 1
Improved survival for patients with lung cancer treated with perioperative immunotherapy
Carolyn J. Presley, Dwight H. Owen
The Lancet (2024)
Closed Access
Maimendong Decoction inhibits lung cancer metastasis by increasing the proportion and killing activity of NK cells
Zhipeng Zhang, Shihui Liu, Yao Wang, et al.
Journal of Ethnopharmacology (2024), pp. 119127-119127
Closed Access
Why and When Do We Invasively Restage After Neoadjuvant Chemoimmunotherapy?
Jonathan Spicer, Tina Cascone, Murry W. Wynes, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 12, pp. e98-e99
Closed Access
Page 1

Scroll to top